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Introduction: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the 
United States. AD is associated with reduced quality of life and substantial financial costs, making it 
burdensome at an individual and population level. Disease severity outcome measures are validated 
tools to assess severity and therapeutic response. Recent consensus statements have identified gold-
standard outcome measures for AD in clinical trials, but further work is needed evaluating outcome 
measures feasible for clinical practice.  
Objective: To investigate the validity and feasibility of the product of investigator global assessment and 
body surface area (IGA x BSA) as an outcome measure for AD in the clinical setting.  
Methods and Results: Retrospective chart review of patients with AD seen in an outpatient dermatology 
clinic at Oregon Health & Science University from 2015-2018 with recorded BSA and IGA revealed 246 
patients comprising 682 clinic visits. We observed strong and statistically significant correlations 
between IGA x BSA and the gold-standard measurement for clinical signs in clinical trials, the Eczema 
Area and Severity Index (r=0.9105, p <0.0001, n=19). IGA x BSA also showed strong correlations with the 
average daily pruritus numerical rating scale (r=0.7108, p <0.0001, n=177) and the patient global 
assessment (r=0.7389, p <0.0001, n=170). 
Conclusions: IGA x BSA is a valid and feasible outcome measure for AD which aligns with patient-
reported disease severity and may be used in real-world clinical practice. 
 
